Medical Network November 7 hearing a few days ago, the well-known IVD Diagnostics issued a notice to not more than 110 million additional shares, 2.3 billion financing, of which 998 million yuan to be used for the acquisition of 64% stake in Guangzhou Di letter letter .
This is in the domestic IVD area, can be considered a larger acquisition, although this transaction is related party transactions.
Public information shows that the current independent medical laboratory is still in its infancy, occupy the medical diagnostic services market share of only about 5% in Europe and the United States, the proportion reached 60% and 35%.
In this way, China's third-party medical inspection industry also has a huge space for development and development opportunities. If it is to reach the first peak of the independent medical inspection agency in the United States, that is, 20% of the medical inspection market share in the late 1980s, China's independent medical testing market there are 10 times the market growth potential.
The first three quarters of this year, Dean Diagnostics achieved operating income of 3.676 billion yuan, an increase of 42%, net profit attributable to parent 250 million yuan, an increase of 33%, non-net profit of 245 million yuan, an increase of 34%, the market performed well.
It is understood that Guangzhou Di will letter is the largest imported IVD products in Guangdong Province proxy One of the providers, working closely with Roche Diagnostics, Ximengmeikang, BDI, Sibia and other world-renowned suppliers, products and services covered by the people of Guangdong Province hospital , Guangzhou Nanfang Hospital, represented by almost all levels of medical institutions clients.
In 2016, the Company recorded a revenue of 910 million yuan and a net profit of 147 million yuan, a revenue of 580 million yuan and a net profit of 90.17 million yuan in January-July 2017. The final assessment of the total equity was RMB1.56 billion. After the acquisition, DI Diagnostics can achieve strategic synergies in South China, especially in Guangdong.
In addition to the acquisition of Guangzhou Di letter, Di diagnosis and Qingdao Chi Ying Medical and Zhengzhou Kang Ze signed a cooperation agreement.
Among them, Qingdao Chiying agent Sysmex, Roche, BD, Cardinal, Sebia and other international brands, with over 500 end-users, tertiary hospital coverage rate of more than 80%.
Zhengzhou Kang Ze Siemens, Sysmex, Meier, Hamerton and other brands of core distributors, product line covering almost all of Henan Province, all the large three, two hospitals.
As of November 6, Dean diagnosed market capitalization of 15.2 billion yuan, and just listed shortly after the third-party inspection agency Golden Domain Medicine, the market value is also less 21 billion. But more than nine, thermal King, Kehua, Yang Pu , Leadman and so much higher.
IVD in the field of China listed companies more than 20, a lot of capital into, who will become the future king?
